What is still unknown about harm
As of September 28, 2026, the Food and Drug Administration (FDA) lacked enough data to tell whether BPC-157 would harm people. A
The short, small human studies do not establish that BPC-157 is safe.
The FDA’s review raises a possible immune response when BPC-157 is injected or given through the nose. A
That means the body could treat the substance as an invader; the review gives no measured rate for that response.
As of September 28, 2026, no FDA-reviewed BPC-157 label explained how it affects other medicines or what it means for pregnancy.
Ask what the health professional knows about your medicines and health history, and what remains unknown. An unanswered question belongs in the discussion.
What a purity figure leaves out
A certificate of analysis is a lab report about a batch, a group made at the same time. Ask to have the report explained in plain words.
In its review checked September 28, 2026, the FDA found many BPC-157 certificates covered purity but left out tests for unwanted material. A
For injections, the FDA names checks for germs, poisons made by bacteria and unwanted particles as key quality tests.
Ask what was tested, which batch it covers and what the results mean. Keep that discussion beside the approval and evidence questions.
Pause when an offer skips a question
A badge stands in for approval
Registration with the FDA does not mean it has approved the product, under the rule reviewed September 26, 2026. B
A form ends the conversation
The Federation of State Medical Boards’ guidance, as of September 26, 2026, requires a way for patients to ask follow-up questions. C
A research label stands in for review
A research-use label does not make BPC-157 an FDA-reviewed product for people, as of September 28, 2026. A
What if an offer says the FDA approved it?
The FDA page says it is current as of April 22, 2026, and reports that groups withdrew their requests to let pharmacies use BPC-157. D
Taking back those requests did not mean FDA approval, and the FDA still listed its safety concerns about BPC-157.
Taking back the requests did not give regular compounding pharmacies permission to use BPC-157 as a raw ingredient, under rules checked September 26, 2026.
When the question needs urgent help
MedlinePlus guidance reviewed September 17, 2026, treats a severe allergic reaction as an emergency. E
For severe symptoms, it directs people to call their local emergency number or go to the nearest emergency room.
Notes behind this page
- FDA review of evidence and product quality (PDF)
It explains the gaps in human harm data and in batch testing.
- Federal rule on registration and listing
A listing is a different matter from an approval.
- Medical board guidance on writing prescriptions and supplying medicines (PDF)
This is guidance for medical boards; state rules govern care.
- FDA page on compounding concerns
Find the entry for this peptide and read the concerns listed with its name.
- MedlinePlus guidance on severe allergic reactions
This is general emergency guidance, not a way to diagnose yourself.